Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH – Get Free Report) shares fell 0.7% during trading on Wednesday . The stock traded as low as $0.61 and last traded at $0.61. 40,294 shares were traded during mid-day trading, a decline of 91% from the average session volume of 433,445 shares. The stock had previously closed at $0.62.
Shuttle Pharmaceuticals Trading Down 5.9 %
The firm has a market capitalization of $2.35 million, a PE ratio of -0.15 and a beta of -1.70. The business’s 50 day simple moving average is $1.05.
Shuttle Pharmaceuticals Company Profile
Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .
Read More
- Five stocks we like better than Shuttle Pharmaceuticals
- The How and Why of Investing in Gold Stocks
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- 3 Stocks to Consider Buying in October
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What Are Dividend Achievers? An Introduction
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for Shuttle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shuttle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.